Novavax, Inc.
Novavax, Inc. (Nasdaq: NVAX) is a biotechnology company that develops vaccines using recombinant protein-based nanoparticles and its Matrix-M adjuvant. Its commercial product is Nuvaxovid, a protein-based COVID-19 vaccine, whose commercialization is led by Sanofi; Novavax also supplies Matrix-M for partner vaccine… From the company’s description.
Over the twelve months to Sep 30, 2026, Novavax, Inc. reported revenue of $411.65M, down 61.3% from a year earlier, and a net loss of $76.73M. Its operating margin was −21.2%, and operations used $238.95M in cash. In fiscal 2025, it reported revenue of $1.12B, up 64.7% from fiscal 2024, and net income of $440.30M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Novavax, Inc. does
In the company’s own words
Novavax, Inc. (Nasdaq: NVAX) is a biotechnology company that develops vaccines using recombinant protein-based nanoparticles and its Matrix-M adjuvant. Its commercial product is Nuvaxovid, a protein-based COVID-19 vaccine, whose commercialization is led by Sanofi; Novavax also supplies Matrix-M for partner vaccine programs, including the R21 malaria vaccine developed by the University of Oxford and manufactured by Serum Institute of India. The company is advancing early-stage programs in areas including C. difficile, shingles, respiratory syncytial virus combinations and pandemic influenza, while pursuing partnerships for its adjuvant and research assets. Its business centers on vaccine research and development, commercialization and supply, and licensing and collaboration agreements rather than separately reported operating segments. Partners including Sanofi, Pfizer, Takeda and Serum Institute of India hold licenses or collaborate on products using Novavax technology. Novavax had approximately 749 employees as of December 31, 2025. Its website is www.novavax.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Biological Products
- Headquarters
- GAITHERSBURG, MD
- Fiscal year end
- December
- CIK
- 1000694
- SIC
- 2836
Financial performance, year by year
Fiscal 2011–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Novavax, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Novavax, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Novavax, Inc.’s bonds, as funds hold them
Funds report holding 2 issues of Novavax, Inc.’s debt, $2.38M at market value — what funds hold, not the company’s total debt. Weighted-average coupon 1.49%, maturing 2027 to 2031.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Novavax, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Novavax, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Novavax, Inc.'s last four quarterly filings that the numbers alone won't show?”